• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

4 FDA-Approved Continuous Glucose Monitoring Systems: An Update

Slideshow

Refresh your memory of 4 CGM systems that received FDA-approval in 2018. Each one offers innovative features to help enhance diabetes care.

FDA-approved CGM devices, continuous glucose monitoring devices, diabetes

In 2018, the FDA issued approvals for several continuous glucose monitors (CGMs), and an expanded indication for a closed-loop artificial pancreas system. Since then, these systems have been rolled out and are currently being marketed in the US. This short slideshow offers compact summaries on 4 of these products which all offer innovative features like extended sensor wear-time, elimination of daily finger stick calibration, and integration with Siri and Google Fit apps.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Impact of Social Determinants of Health on Key Cardiometabolic Measures Amplified by New Research
Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
Related Content
Omnipod 5 System Leads to Significant Glycemic Improvements After Direct Transition from MDI Insulin Plus CGM

Omnipod 5 System Leads to Significant Glycemic Improvements After Direct Transition from MDI Insulin with CGM

Grace Halsey
March 27th 2025
Article

Mean reduction in HbA1c was nearly 1% after transition from MDI plus CGM to Omnipod 5 in the first randomized trial to evaluate the shift in mode of insulin delivery.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits

Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits

Grace Halsey
March 14th 2025
Article

A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose

Sydney Jennings
March 3rd 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes

FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes

Patient Care Editorial Staff
February 14th 2025
Article

Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.

© 2025 MJH Life Sciences

All rights reserved.